Id Biomedical Corporation

Id Biomedical Corporation of Quebec

Josée Hamel

Bernard R Brodeur

Denis Martin

Martine Boyer

Stéphane Rioux

Clement Rioux

Nathalie Charland

Isabelle Charlebois

Julie Couture

Clément Rioux

Catherine Ouellet

Stephane Rioux

Isabelle Pineau

Normand Blais

Steve Labbe

Catherine Vayssier

Annie Charbonneau

France Couture

Mireille Tremblay

Group B(GBS) proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy ofinfection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detectingbacterial infection.

[object Object]

proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy ofinfection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detectingbacterial infection.

Group B(GBS) proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.

Group B streptococcus antigens

The identification of a highly conserved, immunologically accessible antigen at the surface offacilitates treatment, prophylaxis, and diagnosis ofdiseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from threestrains and from onestrain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of thesurface protein, and antibodies that bind to this protein are also disclosed.

The present invention relates to antigens, more particularly antigens of Group B(GBS) () which may be useful to prevent, diagnose and/or treat streptococcal infections.

The present invention relates to polypeptides of()which may be useful for prophylaxis, diagnosis and/or therapy purposes. 

The present invention relates to polypeptides, more particularly polypeptides of()which may be used to prevent, diagnose and/or treat()infection.

Group Bpolypeptides and polynucleotides encoding them are disclosed. Said polypeptides may be useful for the prophylaxis, diagnostic and/or therapy of streptococcal infection in mammals. Also disclosed are recombinant methods of producing the polypeptide antigens as well as diagnostic assays for detecting streptococcal infections, particularly GBS.

The present invention relates to polypeptides of()which may be used for prophy-laxis, diagnostic and/or therapy purposes.

The present invention relates to polypeptides ofwhich may be used for prophylaxis, diagnostic and/or therapy purposes.

polypeptides and polynucleotides encoding them are disclosed. The polypeptides may be useful vaccine components for the prophylaxis or therapy ofinfection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detectingbacterial infection.

Growing community of inventors

Sillery, Canada

Josée Hamel